The Global Cancer Clinical Decision Tools Market Report by The Business Research Company covers cancer clinical decision tools market drivers and restraints, cancer clinical decision tools market size, major players, and the impact of COVID-19 on the cancer clinical decision tools market.
The cancer clinical decision tools market consists of sales of cancer decision support tools and related services. Cancer decision tools are designed to support the general practitioner’s assessment of patients with potential cancer symptoms. The tools do not change the clinical judgment but give more information that is used to inform patient management decisions. The risk is measured based on reading coded information from the patient record including demographic data, medical history, and symptoms.
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer clinical decision tools market. The global cancer clinical decision tools market is expected to grow from $0.36 billion in 2020 to $0.39 billion in 2021 at a compound annual growth rate (CAGR) of 8.3%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer clinical decision tools market is expected to reach $0.55 billion in 2025 at a CAGR of 9%.
Request A Sample For The Global Cancer Clinical Decision Tools Market Report:
Some cancer clinical decision tools market trends include merger and acquisition. In January 2019, Qiagen, a Germany based provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research acquired N-of-One for an undisclosed amount. N-of-One is a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The acquisition of N-of-One will enable QIAGEN to significantly expand its decision-support solutions while offering a broader range of software, content and service-based solutions. It will also enable QIAGEN to expand its clinical bioinformatics capabilities in molecular oncology decision support.
Global cancer clinical decision tools market segments include:
1) By Type: Risk Assessment Tool (RAT), Qcancer.
2) By End-User: Hospital, Clinics.
By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030 At:
The Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides cancer clinical decision tools market overviews, analyzes and forecasts market size, share, cancer clinical decision tools market players, cancer clinical decision tools market segments and geographies, market’s leading competitors’ revenues, profiles and market shares.
The cancer clinical decision tools market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Where To Learn More:
Read Cancer Clinical Decision Tools Global Market Report 2021: COVID-19 Growth And Change To 2030 from The Business Research Company for information on the following:
Data Segmentations: Market Size, Global, By Region And By Country; Historic And Forecast Size, And Growth Rates For The World, 7 Regions And 12 Countries
Market Players Covered: McKesson Corporation, Medical Information Technology Inc., Philips Healthcare, Siemens Healthineers, Elsevier B.V., Macmillan, National Decision Support Company
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Time Series: Five years historic (2015-20) and ten years forecast (2021-2025-2030)
Other Information And Analyses: SWOT analysis, customer information, market product/service analysis – product examples, trends and opportunities, drivers and restraints, key mergers and acquisitions, suggested trend based strategies, impact of COVID-19 on the market, future outlook and potential analysis, key metrics covered: number of enterprises, number of employees, global market in 2021 – countries offering most new opportunities, conclusions and recommendations by expert analysts.
Sourcing And Referencing: Data and analysis throughout the report are sourced using end notes.
Strategies For Participants In The Cancer Clinical Decision Tools Industry: The report explains a number of strategies for companies in the market, based on industry trends and company analysis.
Opportunities For Companies In The Cancer Clinical Decision Tools Sector: The report reveals where the global industry will put on most $ sales up to 2023.
Interested to know more about The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Here is a list of reports from The Business Research Company similar to the Cancer Clinical Decision Tools Global Market Report 2021: